NewsRoom Articles - Page 12 of 154 - PsychedelicNewsWire (PNW)

TuesdayApr 16, 2024 10:00 am

AMA Study Finds Treating Mental-Health Issues with Psilocybin Doesn’t Increase Paranoia Risk

A recently published review has determined that using psilocybin to manage mental-health conditions doesn’t heighten the risk of paranoia. This discovery comes at a time when public interest in the therapeutic potential of psychedelics is increasing. The review was carried out by researchers at Larkin University, the University of Georgia and Palm Beach Atlantic University, who were focused on better understanding the potential negative effects of psilocybin therapy. For their study, the researchers reviewed six randomized, double-blind clinical trials with a total of 528 patients, where psilocybin was administered to treat depression and anxiety. They used ClinicalTrials.gov, Web of Science…

ThursdayApr 11, 2024 10:00 am

Psilocybin Could Help in Combating Diabetes

Diabetes is a chronic illness characterized by high levels of blood sugar. There are different types of diabetes, the most common being types I and II. Latest data estimates that by 2045, more than 700 million individuals globally could be afflicted with the illness as its prevalence continued to rise. Researchers have commenced studies into whether psilocybin may help fight the effects of diabetes. Psilocybin is the primary psychoactive compound found in various species of hallucinogenic mushrooms. In the last couple of years, the compound’s therapeutic potential has been recognized, particularly for mental health disorders such as anxiety, depression and…

TuesdayApr 09, 2024 10:00 am

Missouri to Use $10M from Opioid Funds to Study Psilocybin

Legislators in the House of Representatives in the state of Missouri have awarded preliminary approval to a budget measure that would allocate $10 million from opioid settlement funds to study grants focused on researching psilocybin’s use in treating opioid-use disorder. The initiative, HB 2010, was amended in the House. One amendment made in a committee last week would have allocated the $10 million toward conducting research on ibogaine as an opioid-use disorder treatment. This provision was modified to fund studies on psilocybin instead. Ibogaine’s addition to HB 2010 was facilitated by Representative Chad Perkins, a long-time law enforcement officer. The…

ThursdayApr 04, 2024 10:00 am

More Psychedelic Users Reporting Symptoms of HPPD

Hallucinogenic persistent perception disorder (HPPD) is an intoxication disorder caused by psychedelic drugs that encompasses a range of visual disturbances that occur in different time frames. The disorder also causes extreme anxiety as well as out-of-body sensations and is marked by shame as well as stigma. There are two types of HPPD; the first is characterized by brief flashbacks, while individuals with the second type of HPPD experience symptoms that can last anywhere between a couple of months to their whole lives. Dr. Anneliese McConnell, a researcher at Western Sydney University, reports that HPPD affects more than 5% of psychedelic…

TuesdayApr 02, 2024 10:00 am

Research Findings Promising as Scientists Study Placebo Effect in Psychedelic Treatment

Recent research assessed how patient expectations influenced the outcomes of psychedelic treatments in comparison to conventional treatments. This comes as the global impact of depression is being felt in different parts of the world and the need for alternative treatments increases. For a long time, selective serotonin re-uptake inhibitors (SSRIs) have been prescribed to manage depression. While these drugs do perform better than placebos, they aren’t effective for all individuals. Psychedelic-assisted therapy has been heralded as a new approach to manage mental-health conditions such as depression, promising a range of benefits with only a few sessions. However, some questions on…

ThursdayMar 28, 2024 10:05 am

Indiana Governor Enacts Bill Funding Psilocybin Research for First Responders, Veterans

Governor Eric Holcomb of Indiana recently signed a measure that includes provisions to fund clinical trials on psilocybin’s therapeutic benefits. The measure, which primarily focuses on healthcare issues, was recently amended to include language on psychedelics. The reform provisions that legislators included to the broader measure were obtained from a standalone bill from Senator Ed Charbonneau, which cleared the Senate in February. In a press release, Charbonneau stated that the bill’s intention was to provide funds to help research institutions in the state in conducting research on the possible use of psilocybin in the treatment of mental-health conditions, with a…

TuesdayMar 26, 2024 10:00 am

University of Calgary Researchers Begin Testing Psilocybin as AUD Treatment

University of Calgary scientists want to conduct a trial on the use of psilocybin as a treatment for alcohol use disorder (AUD). The trial will be carried out at the Hotchkiss Brain Institute and will include 128 individuals with alcohol use disorder. Each of the participants will undergo sessions prior to and after treatment; they will each also be assigned to trained therapists to take them through talk-therapy. In a news release, the trial’s principal investigator, Dr. Leah Mayo, revealed that team members would start the study with psychotherapy then administer psilocybin and observe whether this improved the therapy’s effectiveness.…

ThursdayMar 21, 2024 10:00 am

Study Suggests Psilocybin Mushrooms Trigger Enhanced Benefits on Brain Compared to Synthetic Versions

New research suggests that hallucinogenic mushrooms that contain psilocybin may be useful in the treatment of conditions such as anxiety, post-traumatic stress disorder and obsessive-compulsive disorders. Professor Bernard Lerer, the author of the study, stated that researchers were interested in psychedelics’ potential in managing treatment-resistant psychiatric disorders, including post-traumatic stress disorder, depression and even schizophrenia. Lerer, a psychiatry professor and the director of Hebrew University’s Hadassah BrainLabs Center for Psychedelic Research, explained that many reports had proposed that using extracts from mushrooms that contain psilocybin could have effects that were quantitatively and qualitatively different from chemical psilocybin, which is what…

TuesdayMar 19, 2024 11:00 am

Study Shows Psilocybin Reduces Brain’s Reaction to Angry Faces

New research has discovered that psilocybin decreases the amygdala region’s response to seeing images of angry faces. The amygdala is responsible for processing emotions, particularly those linked to anxiety and fear. This region in the brain also links emotions to other things such as senses, memories and learning. This region’s activity affects social interactions as well as behaviors, including avoidance and aggression. Psilocybin is a compound that naturally occurs in some mushroom species known as magic mushrooms. The compound’s psychoactive properties can produce altered states of consciousness, which may include changes in an individual’s mood, perception and thought patterns. For…

ThursdayMar 14, 2024 11:00 am

How Psychedelics Could Enable Soldiers Beat Trauma

Data from Veterans Affairs estimates that more than 120,000 veterans in the United States have died by suicide. Many more in America and other parts of the globe struggle with post-traumatic stress disorder as conflicts rear their heads globally. In Ukraine, the ministry of health estimates that close to four million individuals are living with post-traumatic stress disorder. To help manage this, many have turned to psychedelics, and for good reason. Last month, the country’s special parliamentary commission voted to set up a working group that would investigate the effectiveness of MDMA-assisted therapy on post-traumatic stress disorder. In a statement,…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000